Good news comes from the United States amid the corona virus pandemic which is in most countries around the world.
Treatment of corona virus patients conducted at a hospital in Chicago using remdesivir, an antiviral drug produced by the US biotechnology company, Gilead Sciences Inc. is showing positive results.
At present the hospital is conducting clinical trials on the drug.
The clinical trial was closely monitored to see rapid recovery in fever and respiratory symptoms, with almost all patients discharged in less than a week.
Launching STAT News, remdesivir was one of the first drugs identified as having the potential to impact SARS-CoV-2, a new type of corona virus that causes Covid-19 in laboratory tests.
Gilead clinical trial results are eagerly awaited.
And positive results will likely lead to quick approval by the Food and Drug Administration and other regulatory and drug regulatory bodies.
If it is safe and effective, it can be an approved treatment for the first time against Covid-19 disease.
The University of Chicago Department of Medicine recruited 125 people with Covid-19 into two Gilead Phase 3 clinical trials.
Of these people, 113 had severe illness. All patients were treated with remdesivir infusion every day.
“The best news is that most of our patients are out, this is good. We only lost (died) two patients, “said Kathleen Mullane, an infectious disease specialist at the University of Chicago who oversees remdesivir research for hospitals.
His comments were delivered this week during a video discussion about the results of the trial with other University of Chicago faculty members.
• Corona Virus Test No Need to RS with Drive Thru Service, Available in Indonesia
The discussion was recorded and STAT News obtained a copy of the video.
The results only show a portrait of the effectiveness of remdesivir.
However, no other clinical data from the Gilead study have been released to date.
Last month, President of the United States, Donald Trump touted the potential of remdesivir as he has for many treatments that have not yet been proven, and said that “it seems (treatment with remdesivir) has very good results.”
In a statement on Thursday, Gilead said: “What we can say at this stage is that we are waiting for data from ongoing studies (to) be available.”
Gilead said they expect results for tests involving severe cases in April.
Mullane said during his presentation that data for the first 400 patients in the study would be “locked” by Gilead on Thursday, meaning that the results could come at any time.